InvestorsHub Logo
Followers 96
Posts 4821
Boards Moderated 0
Alias Born 02/07/2021

Re: FeMike post# 595301

Tuesday, 05/23/2023 10:40:11 AM

Tuesday, May 23, 2023 10:40:11 AM

Post# of 703877
Most financial advisors will keep their clients away from biotechnology as a sector especially now that we are in a bear market. I didn't invest in Northwest Biotherapeutics with the hope that pensioners would pile into this stock. I am looking at whether management can address global GBM demand. The investors will then follow.

We all know about the cash burn rate. This has been a challenge which management have dealt with for years. As a result of their investment in R&D we have a vaccine which could treat all solid tumors as well as multiple manufacturing processes to meet global demand for the GBM indication. That's $100 billion market cap for newly diagnosed and recurrent patients.

I really think your arguments are elementary distractions as we are already aware of this "risk" you cite which really happens to be a standard business practice in the biotechnology sector.

Those who didn't know about this fact, our R&D expenses, haven't done their due diligence.

They probably shouldn't own this stock.

The reasons I do are below.


https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

https://pubmed.ncbi.nlm.nih.gov/37129737/

http://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pdf

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671





















Bullish
Bullish

Do your own research. I am not providing legal or investment advice. This is an anonymous forum for entertainment purposes only. Don't trust anything you read.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News